If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGWP.L Regulatory News (GWP)

  • There is currently no data for GWP

Director/PDMR Shareholding

14 Sep 2016 17:27

RNS Number : 8758J
GW Pharmaceuticals PLC
14 September 2016
 

Notification and public disclosure of transactions by persons discharging

managerial responsibilities and persons closely associated with them

 

1.

Details of the person discharging managerial responsibilities / person closely associated

a.

Name

Dr Stephen Wright

2.

Reason for the notification

a.

Position/status

Director/Chief Medical Officer

b.

Initial notification

/Amendment

Initial notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a.

Name

GW Pharmaceuticals PLC

b.

LEI

 

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a.

Description of the

Financial instrument, type of instrument

Identification code

 

Ordinary shares of 0.1p each

ISIN: GB0030544687

b.

Nature of the transaction

Exercise of share options to acquire ordinary shares.

 

c.

Price(s) and volume(s)

 

Price(s)

 28.15p

Volume(s)

198,288

 

Ordinary shares acquired pursuant to option exercise

d.

Aggregated information

· Aggregated volume

· Price

 

 

 

n/a

e.

Date of the transaction

13 September 2016

f.

Place of the transaction

 London

 

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a.

Description of the

Financial instrument, type of instrument

Identification code

Ordinary shares of 0.1p each and American Depositary Shares

 

 Ordinary Shares: ISIN: GB0030544687

American Depositary shares: ISIN: 36197T1034

b.

Nature of the transaction

Conversion of 198,288 Ordinary shares into American Depositary Shares (12 to 1 conversion ratio) to create 16,524 ADSs

 

c.

Price(s) and volume(s)

 

Price(s)

 -

Volume(s)

16,524

 

ADS's issued upon conversion of 198,288 Ordinary shares

d.

Aggregated information

· Aggregated volume

· Price

 

 

 

n/a

e.

Date of the transaction

13 September 2016

f.

Place of the transaction

Outside a trading venue

 

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a.

Description of the

Financial instrument, type of instrument

Identification code

 

 

American Depositary Shares

ISIN: 36197T1034

b.

Nature of the transaction

Sale of American Depositary shares

 

c.

Price(s) and volume(s)

 

Price(s)

 $98.75

Volume(s)

16,524

 

ADS's sold

d.

Aggregated information

· Aggregated volume

· Price

 

 

 

n/a

e.

Date of the transaction

13 September 2016

f.

Place of the transaction

Nasdaq, New York

 

 

Explanatory note: On 13 September 2016 Dr Stephen Wright exercised options to acquire 198,288 0.1 pence Ordinary shares for an average exercise price of 28.15 pence per share. These were immediately converted into 16,524 American Depositary Shares and sold via Nasdaq for an average price of $98.75 per ADS. The sale represents less than 0.1% of shares in issue. This sale of shares by Dr Stephen Wright is in accordance with the disclosures contained within the prospectus dated 14 July 2016 whereby the sale of up to 200,000 Ordinary shares by Dr Wright was agreed by the underwriters to be specifically excluded from the lock-up arrangements entered into by the Directors of the Company.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
DSHLLFFRARISLIR
Date   Source Headline
18th Feb 201410:20 amRNSBlocklisting Interim Review
12th Feb 20141:47 pmRNSAdditional Listing
10th Feb 20145:00 pmRNSPresenting at Leerink Global Healthcare Conference
5th Feb 20147:00 amRNSQ1 2014 Financial Results and Operational Progress
31st Jan 20143:17 pmRNSHolding(s) in Company
29th Jan 20147:00 amRNSNotice of Results
17th Jan 20145:11 pmRNSHolding(s) in Company
16th Jan 201411:13 amRNSAdditional Listing
15th Jan 20144:34 pmRNSHolding(s) in Company
15th Jan 20144:33 pmRNSHolding(s) in Company
14th Jan 20144:23 pmRNSClosing of U.S. Follow-on Offering of Nasdaq ADSs
14th Jan 20147:00 amRNSAgreement with Ipsen for Sativex in Latin America
13th Jan 20145:00 pmRNSHolding(s) in Company
13th Jan 20145:00 pmRNSHolding(s) in Company
9th Jan 20147:00 amRNSRaises $87.9m on NASDAQ in U.S. Follow-On Offering
6th Jan 201412:18 pmRNSResults of General Meeting
6th Jan 201412:13 pmRNSFiles Amendment to Registration Statement
20th Dec 20132:05 pmRNSNotice of General Meeting and Follow-On Offering
11th Dec 20137:00 amRNSU.S. Patent Allowance for Cannabinoids in Glioma
6th Dec 20135:52 pmRNSPublication of UK Annual Report and Accounts
2nd Dec 20137:00 amRNSPresenting at Piper Jaffray Health Care Conference
29th Nov 20132:00 pmRNSBlocklisting Application
27th Nov 20137:00 amRNSSativex Regulatory Approval in Switzerland
26th Nov 20135:51 pmRNSDirector/PDMR Shareholding
26th Nov 20137:00 amRNSFiling of U.S. Annual Report on Form 20-F
19th Nov 20137:00 amRNSFinal Results
18th Nov 20136:00 pmRNSGW Presenting at Jefferies Healthcare Conference
15th Nov 20137:00 amRNSUpdate on Epidiolex in Childhood Epilepsy
12th Nov 20137:01 amRNSNotice of Results
11th Nov 20137:00 amRNSPhase 1b/2a trial for Glioblastoma Multiforme
21st Oct 20137:00 amRNSSuccessful Closing of Mutual Recognition Procedure
2nd Oct 20138:00 amRNSNew Sativex Data at ECTRIMS
24th Sep 20132:01 pmRNSGrant of Options
23rd Sep 201311:41 amRNSAgreement on Sativex Pricing in Germany
20th Sep 20137:00 amRNSPresenting at Aegis Capital Healthcare Conference
18th Sep 20137:00 amRNSGW Commences Trial of GWP42006 for Epilepsy
19th Aug 20137:00 amRNSBlocklisting Interim Review
14th Aug 20137:00 amRNSInvestigational New Drug Application for Sativex
8th Aug 20137:00 amRNSPresenting at the Canaccord Genuity Conference
5th Aug 20137:00 amRNS2013 Third Quarter Financial Results
5th Aug 20137:00 amRNSSativex MS Spasticity Cognition Study Results
22nd Jul 20137:00 amRNSFiles new application to expand Sativex to France
15th Jul 20137:00 amRNSNotice of Results
8th Jul 20137:00 amRNSProduct Launch
4th Jul 20138:31 amRNSHolding(s) in Company
10th Jun 201312:53 pmRNSDirector/PDMR Shareholding
3rd Jun 20137:00 amRNSSecond Quarter Financial Results
30th May 20135:30 pmRNSExercise of Over-Allotment Option
14th May 20131:00 pmRNSNotice of Results
10th May 20134:28 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.